Dogwood Therapeutics, Inc.
Dogwood Therapeutics is a pre-revenue, development-stage biopharmaceutical company developing medicines for pain and neuropathy. Its pipeline includes Halneuron®, a non-opioid sodium channel modulator in late-stage clinical development for chemotherapy-induced neuropathic pain, and SP16, a synthetic anti-inflammatory peptide in early Phase 1 development for neuropathy and nerve damage. The company also has antiviral programs, including IMC-1 and IMC-2, combinations intended to suppress herpesvirus activation and replication and being explored for conditions including fibromyalgia and Long-COVID. Dogwood develops drug candidates and relies on third-party contractors to manufacture clinical supplies. If its candidates receive regulatory approval, it plans to use sales and marketing agreements with pharmaceutical companies to reach anesthesiologists, oncologists and primary care physicians. Dogwood is headquartered in Alpharetta, Georgia.
No enriched coverage for $DWTX in the last 7 days.
No SEC Form 4 filings for $DWTX in the last 30 days.
See all $DWTX insider activity →Dogwood Therapeutics, Inc. (DWTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Dogwood Announces $5 Million Private Placement with CK Life Sciences Int’l., (Holdings) Inc. - Largest Shareholder Increases Position as Dogwood Advances Halneuron® Toward Topline Phase 2b Data Readout in November 2026 - - Expected Proceeds from the Investment Enab
Dogwood Therapeutics (DWTX) raises $5M from CK Life Sciences via a private placement of 4.1M shares at $1.22 each. Funds will support Phase 3 prep for Halneuron and extend runway to March 2027. Halneuron is in Phase 2b trial for chemotherapy-induced neuropathic pain, with data expected in November 2026.
Dogwood Therapeutics (DWTX) completed enrollment in its Halneuron Phase 2b trial for chemotherapy-induced neuropathic pain, with 239 patients. Topline results are due in November 2026. Halneuron, a non-opioid analgesic, has FDA Fast Track designation. DWTX stock is currently trading at $1.87.
Recent DWTX coverage spans corporate actions, technology and earnings.
The capital raise provides funding for Phase 3 preparation and working capital, likely supporting the stock price.
The capital raise supplies needed funding but dilutes existing shares.
Enrollment completion reduces execution risk and sets up a November data catalyst.
Trial progress may attract speculative interest ahead of fall readout.
Positive interim data may lift the stock ahead of the Phase 2b readout and future FDA engagement.
AlphAI scores every news story that mentions DWTX with an AI model for sentiment and relevance, and aggregates insider trades from Dogwood Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Dogwood Therapeutics, Inc. (DWTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Dogwood Announces $5 Million Private Placement with CK Life Sciences Int’l., (Holdings) Inc. - Largest Shareholder Increases Position as Dogwood Advances Halneuron® Toward Topline Phase 2b Data Readout in November 2026 - - Expected Proceeds from the Investment Enab
2 min readDogwood Therapeutics (DWTX) raises $5M from CK Life Sciences via a private placement of 4.1M shares at $1.22 each. Funds will support Phase 3 prep for Halneuron and extend runway to March 2027. Halneuron is in Phase 2b trial for chemotherapy-induced neuropathic pain, with data expected in November 2026.
2 min readDogwood Therapeutics (DWTX) completed enrollment in its Halneuron Phase 2b trial for chemotherapy-induced neuropathic pain, with 239 patients. Topline results are due in November 2026. Halneuron, a non-opioid analgesic, has FDA Fast Track designation. DWTX stock is currently trading at $1.87.
2 min readModular Medical (MODD) rose 13.48% in overnight trading after a 23.37% drop earlier, planning a 2026 launch for its Pivot tubeless patch pump. Jin Medical (ZJYL) gained 20.79% with no specific news. InnovAge (INNV) increased 9.51% after reporting a 15.9% revenue rise. Pyxis Oncology (PYXS) climbed 5% ahead of a key clinical update. Pulse Biosciences (PLSE) fell 2.48% despite clinical trial progress. Dermata (DRMA) rose 7.20% after launching its Tome skincare brand. Dogwood Therapeutics (DWTX) ga
3 min readDogwood Therapeutics (DWTX) reported interim results from its Phase 2b trial of Halneuron for neuropathic pain, showing trends toward separation from placebo. The company plans to expand the trial to 210-240 patients for 80% statistical power. Dogwood is also developing synthetic tetrodotoxin for future studies and aims to begin Phase 3 trials in 2025, with a potential new drug application submission in 2029.
2 min readAethlon Medical (AEMD) reported a 12% narrower Q1 loss and progress in its Hemopurifier study, with shares up 17.5%. Quoin Pharmaceuticals (QNRX) surged 34% pre-market on positive QRX003 data and a $50M financing. Dogwood Therapeutics (DWTX) gained 12% as its Halneuron trial advances. Freenome (FRNM) rose 7% after FDA Breakthrough Device Designation for its lung cancer test.
3 min readDogwood Therapeutics, Inc. (DWTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Dogwood Therapeutics Announces Second Quarter 2026 Financial Results - Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026, 217 patients enrolled – - Commencement of Phase 2b Long-Term Extension Study to assess H
6 min readDogwood Therapeutics, Inc. (DWTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. DOGWOOD THERAPEUTICS, INC._June 16, 2026 0001818844 false --12-31 0001818844 2026-06-16 2026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Da
3 min readATLANTA, Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- Dogwood Therapeutics, Inc. DWTX ( the "Company" ) , a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announces it will participate in the H.C. Wainwright 27th Annual Global ...
3 min readATLANTA, Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- Dogwood Therapeutics, Inc. ( Nasdaq: DWTX ) ( the "Company" ) , a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announces it will participate in the H.C.
2 min read
